For cancer vaccines, RNA lipid nanoparticles, either alone or in combination with ICBs, induced durable clinical responses, associated with strong CD4 + and CD8 + T cell immunity against the vaccine antigens [287]. The gene discussed is CD8A; the disease is cancer.